Peter Wirth, J.D.
Peter Wirth is Chairman of FORMA Therapeutics Holdings, LLC, a cancer drug discovery company. Prior to that, Peter served as a co-founder, President and Director of Lysosomal Therapeutics, Inc., a neurodegeneration company. Before co-founding Lysosomal, Peter was an Advanced Leadership Fellow at Harvard University. For 15 years prior to that, Peter was a senior executive at Genzyme Corporation, where he held the roles of Executive Vice President, Legal and Corporate Development, Chief Risk Officer and Corporate Secretary. His responsibilities included oversight of the corporate development and legal departments, and management of the company’s enterprise risk management activities. Before joining Genzyme, Peter was a partner at Palmer & Dodge, a Boston law firm; there, he was head of the firm’s biotechnology practice group and served as Genzyme’s outside general counsel. He received his BA from the University of Wisconsin, Madison, and his J.D. from Harvard Law School.